The Burden of Hepatitis C Virus Infection in Punjab, India:A Population-based Serosurvey by Sood, Ajit et al.
                          Sood, A., Suryaprasad, A., Trickey, A., Kanchi, S., Midha, V., Foster, M., ...
Averhoff, F. (2018). The Burden of Hepatitis C Virus Infection in Punjab,
India: A Population-based Serosurvey. PLoS ONE, 13(7), [e0200461].
https://doi.org/10.1371/journal.pone.0200461
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1371/journal.pone.0200461
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Public Library of
Science at https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0200461 . Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
RESEARCH ARTICLE
The burden of hepatitis C virus infection in
Punjab, India: A population-based serosurvey
Ajit Sood1, A. Suryaprasad2, A. Trickey3*, S. Kanchi4, V. Midha1, M. A. Foster2,
E. Bennett2, S. Kamili2, F. Alvarez-Bognar5, S. Shadaker6, V. Surlikar4, R. Garg7, P. Mittal8,
S. Sharma9, M. T. May3, P. Vickerman3, F. Averhoff2
1 Dayanand Medical College, Ludhiana, Punjab, India, 2 Division of Viral Hepatitis, Centers for Disease
Control and Prevention, Atlanta, GA, United States of America, 3 Population Health Sciences, University of
Bristol, Bristol, United Kingdom, 4 MSD India Pvt. Ltd., Mumbai, India, 5 Merck & Co. Inc., Kenilworth, NJ,
United States of America, 6 CDC Foundation, Atlanta, GA, United States of America, 7 Guru Gobind Singh
Medical College and Hospital, Faridkot, Punjab, India, 8 Mittal Liver and Gastroenterology Centre, Patiala,
Punjab, India, 9 College of Nursing, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
* adam.trickey@bristol.ac.uk
Abstract
Introduction
Hepatitis C virus (HCV) infection prevalence is believed to be elevated in Punjab, India; how-
ever, state-wide prevalence data are not available. An understanding of HCV prevalence,
risk factors and genotype distribution can be used to plan control measures in Punjab.
Methods
A cross-sectional, state-wide, population-based serosurvey using a multi-stage stratified
cluster sampling design was conducted October 2013 to April 2014. Children aged5 years
and adults were eligible to participate. Demographic and risk behavior data were collected,
and serologic specimens were obtained and tested for anti-HCV antibody, HCV Ribonucleic
acid (RNA) on anti-HCV positive samples, and HCV genotype. Prevalence estimates and
adjusted odds ratios for risk factors were calculated from weighted data and stratified by
urban/rural residence.
Results
5,543 individuals participated in the study with an overall weighted anti-HCV prevalence of
3.6% (95% Confidence Interval [CI]: 3.0%–4.2%) and chronic infection (HCV Ribonucleic
acid test positive) of 2.6% (95% CI: 2.0%–3.1%). Anti-HCV was associated with being male
(adjusted odds ratio 1.52; 95% CI: 1.08–2.14), living in a rural area (adjusted odds ratio
2.53; 95% CI: 1.62–3.95) and was most strongly associated with those aged 40–49
(adjusted odds ratio 40–49 vs. 19–29-year-olds 3.41; 95% CI: 1.90–6.11). Anti-HCV preva-
lence increased with each blood transfusion received (adjusted odds ratio 1.36; 95% CI:
1.10–1.68) and decreased with increasing education, (adjusted odds ratio 0.37 for gradu-
ate-level vs. primary school/no education; 95% CI: 0.16–0.82). Genotype 3 (58%) was most
common among infected individuals.
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Discussion
The study findings, including the overall prevalence of chronic HCV infection, associated
risk factors and demographic characteristics, and genotype distribution can guide preven-
tion and control efforts, including treatment provision. In addition to high-risk populations,
efforts targeting rural areas and adults aged40 would be the most effective for identifying
infected individuals.
Introduction
There are an estimated 70 million people living with hepatitis C Virus (HCV) infection around
the world.[1] Persons living with HCV infection are at risk of developing liver cirrhosis and
progressing to end stage liver disease and liver cancer (hepatocellular carcinoma).[2–7] Glob-
ally, an estimated 700,000 people die annually due to complications related to HCV infection.
[8]
The World Health Organization (WHO) has set ambitious targets to eliminate HCV infec-
tion as a public health problem by 2030.[9] In order to achieve these targets, which include
reduction of new infections by 90% and deaths by 65%, there is a need to increase prevention
strategies and access to treatment. Treatment for HCV has improved dramatically with the
addition of direct acting antivirals (DAAs), which are easy to take oral regimens that are highly
effective, have minimal side effects, and achieve cure rates of over 90%.[10, 11] In order to
establish effective prevention and treatment programs, there is a need to understand the epide-
miology and burden of disease in the country or community. However, such data are lacking
in many countries, particularly in lower and middle income countries which shoulder most of
the burden.[12] There are significant geographical variations in prevalence patterns and geno-
type distribution globally,[12, 13] with populations in North America and Western Europe
having anti-HCV prevalence rates generally less than 1%, while in some areas of Asia and the
Middle East, prevalence rates exceed 5%.[1, 12–15] In India, where genotype 3 is thought to be
most common,[16] population based studies on HCV infection prevalence are lacking, and
the epidemiology is not well described. Some studies from India suggest the HCV prevalence
may be low, however, there are significant variations within regions and sub-populations, with
some studies demonstrating very high prevalence rates.[15, 17]
Population HCV seroprevalence data are lacking in Punjab, a state in Northern India with
an estimated population of 28 million.[18] A survey conducted in one district of Punjab in
2003 found a 5% anti-HCV positive rate; in this study, infection was associated with reuse of
needles and syringes, history of surgery, and history of dental extraction.[19] Elevated rates of
HCV infection have also been identified among high risk populations (eg. people who inject
drugs [PWID]) in Punjab,[20, 21] which may reflect the growing epidemic of injection drug
use, a high-risk behavior for HCV infection.[22]
Epidemiological assessment of the burden of disease and related risk factors in the state are
essential for public health planning strategies to combat this disease. This study assessed the
prevalence of HCV infection in Punjab and identify risk factors associated with the disease.
Materials and methods
Sample design
A cross-sectional seroprevalence survey was conducted in the state of Punjab, India during
October 2013 –April 2014. Punjab is divided into three major geographical areas, Doaba,
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Majha, and Malwa which contain a total of 22 districts. The survey sample size was calculated
to enable estimation of HCV prevalence among individuals age 5 years and older, using the
statistical software PASS (NCSS, LLC. 2011 Kaysville, Utah, USA). For expected HCV preva-
lence of 5% with a 95% confidence interval (CI) of 4–6%, the effective sample size was esti-
mated to include 1,924 households; and assuming a design effect of 2 and overall response rate
of 70%, the target sample size was 5,500 individuals.
The study included testing for past and current HCV infection, past infections with hepati-
tis A virus and hepatitis E virus, and past or current infection with hepatitis B virus (HBV).
Results will only be presented for HCV infection in this report. The sample size of 5,500 indi-
viduals was expected to be large enough to produce combined estimates with relative standard
errors of 10–20%. For stratified analysis, a minimum sample size of 1,000 per strata was
expected to produce estimates with relative standard errors of 25% or less. Estimates based on
relative standard errors >25% are considered unreliable.
The survey used a multi-stage stratified cluster sampling design using 2011 Punjab Census
data,[18] and 10 of the 22 districts in Punjab were selected with probability proportionate to
size. In rural areas, 22 sub districts and 87 villages were selected proportionate to size, and 813
households were systematically selected in groups of five. To ensure the selection of a sufficient
number of households in rural areas, villages with fewer than five households were excluded,
and villages with 5–49 households were combined with neighboring villages, for a minimum
of 50 households per sampling unit. In urban areas, 13 sub districts and 41 wards were selected
proportionate to size; 1 census enumeration block of 150–200 households was randomly
selected per ward; and 586 households were systematically selected in groups of five. For large
sampling units, villages and census enumeration blocks with 500 or more households were
divided into three or more segments and two segments were selected proportionate to size.
All household residents and guests 5 years of age and older of selected household residents
who stayed at the household the previous night were eligible to participate in the study.
Selected adults18 years of age who provided informed consent, and children age 5–17 years
who provided assent and informed parental/guardian consent were included. Pregnant
women were included, since participation in the study did not pose any risk to the mother or
her unborn child. Individuals under 5 years of age and those who did not provide consent or
assent were not included. No replacement was made if selected household was not available
during data collection.
Data collection
Trained survey teams consisting of a doctor, a phlebotomist, a nurse and a social worker visited
selected households and administered the survey questionnaire, after obtaining informed con-
sent and assent from children willing to participate. The study questionnaire was administered
as a face-to-face interview and inquired about socio-demographic data, medical history, lifestyle
information, obstetric history (if applicable), and potential exposures to HCV, including health-
care and lifestyle associated exposures. Each completed questionnaire was reviewed in the field
by the team doctor, and if inconsistencies or gaps were identified, an attempt to correct or fill in
the missing information was made by revisiting the surveyed individual before leaving the clus-
ter. Each completed interview was labeled with a bar code with a unique identifier.
After completing the interview, a blood sample of approximately 16ml was drawn in a
serum separator tube and labeled with a barcode matching the interview form completed by
the study subject. Within one hour of collection, the sample was centrifuged for 15 minutes at
3,000 revolutions per minute. Separated serum was pipetted into 2ml cryovials, which were
also labeled with bar codes matching the study subjects. Up to eight aliquots of sample per
Prevalence of hepatitis C virus infection in Punjab, India
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subject were prepared and frozen at -80C. Specimens were shipped every 2 weeks to a central
laboratory (Oncquest Laboratories Ltd) in Delhi for testing. All samples were tested for anti-
HCV (Vitros Immunodiagnostic Anti-HCV, Johnson and Johnson Co., New Brunswick, NJ,
USA) and all anti-HCV positive samples were tested for HCV RNA (COBAS1 TaqMan1
HCV Test, Roche, Indianapolis, IN, USA). All HCV RNA positive samples were genotyped by
Linear Array HCV genotyping test (Roche, Indianapolis, IN, USA). Survey participants who
tested positive for anti-HCV were considered infected with HCV, regardless of HCV RNA
results. Survey participants who tested positive for anti-HCV and HCV RNA were considered
to have current infection, and those that tested anti-HCV positive and HCV RNA negative
were considered to have past infection. Specimens were also tested for hepatitis A virus, hepati-
tis B virus and hepatitis E virus markers of infection (methods and results not described in this
report). Unused blood was disposed of as per healthcare waste management guidelines and all
specimens were destroyed following completion of the study.
Counseling and notification of test results
For consenting participants, pretest counseling and educational brochures on HCV transmis-
sion and prevention were administered prior to interview and venipuncture. Study partici-
pants were notified of their test results for HCV, HBV, HAV, and HEV infection or immunity
by telephone and mail within three weeks of the interview date. Patients found to have current
(active) HBV or HCV infection were offered post-test counseling by appointment. All partici-
pants were counseled about measures to prevent the risk of transmission of the various forms
of viral hepatitis.
Ethical considerations
The protocol for this study underwent approval from the Institutional Review Board (IRB) at
Dayanand Medical College, Ludhiana, and the Merck Investigator Initiated Study Protocol-
Review Committee (MISP-RC). Participation was voluntary and confidentiality was strictly
adhered to during the survey. Written consent was documented by the study subject’s dated
signature or thumbprint on a consent form along with the dated signature of the person who
conducted the consent discussion. A copy of the consent form was given to the subject prior to
participating in the survey. Consent forms were available in English, Punjabi and Hindi. If the
subject was illiterate, a witness was present during the entire informed consent reading and
discussion. Afterward, the subjects signed and dated the consent if literate, or a thumb impres-
sion was taken. The witness also signed and dated the consent form along with the study staff
who read and discussed the consent. Children5 years and <18 years of age provided assent
in addition to having parental permission.
Statistical methods
Analyses of the survey data were weighted according to the population sizes of the wards and
villages estimated from the 2011 population census. This weighting was stratified by urban/
rural status. The HCV prevalence was estimated for the state as a whole, by urban/rural resi-
dence, and by district. A χ2 test was used to examine whether the proportion of HCV RNA
positive patients with each genotype differed by district. Participant characteristics and preva-
lence of HCV risk factors were tabulated for those testing positive for anti-HCV and those test-
ing positive for HCV RNA. The variables included in these tabulations were district, age-
group (5–18, 19–29, 30–45, 46–60, >60), sex, urban/rural status, household income in rupees
(<20,000,20,000), education status (never educated/primary education, middle/secondary,
graduate/above), the number of injections received in the last 6 months (0, 1–3, 4–8, >8), who
Prevalence of hepatitis C virus infection in Punjab, India
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administered the last injection received (Medical Doctor, Registered Nurse/Medical Practi-
tioner, Other/Unknown (including chemists and unlicensed practitioners), the number of life-
time blood donations (0, 1–3, 4–6, >7), the number of blood transfusions received (0, 1–3,
>3), if ever received a permanent tattoo, if ever used injectable drugs, or had ever received
renal dialysis. Proportions and numbers presented in the tabulations were weighted to repre-
sent the population surveyed. Tabulations were stratified by urban/rural status. We estimated
the association of patient characteristics and HCV risk factors with HCV status using weighted
logistic regression models for the total survey population, stratified by urban/rural status, and
clustered by household. Age, the number of injections received in the last 3 months, the num-
ber of times the person had donated blood, the number of blood transfusions received were
included in models as continuous variables. Results are presented as weighted unadjusted and
mutually adjusted odds ratios (OR) of having a positive anti-HCV test, with 95% confidence
intervals (CI). We also estimated the association of the year of the first blood transfusion
received (grouped as before 2002, 2002 or later year, year unknown, and no blood transfusions
received; of note, blood bank testing for HBV and HCV became mandatory in Punjab by law
in 2002) with HCV status. We used the same mutually adjusted model as above, but instead of
including the number of blood transfusions we included the year of first receiving a blood
transfusion. A sensitivity analysis excluded participants under 18 years of age because some
risk factors only applied to adults, and another sensitivity analysis (not stratified by urban/
rural status) only included participants aged 40–59 years of age as these were the two highest
prevalence age groups.
We examined the number of injections (categorized: 0, 1–3, 4–8,>8) received in the last 6
months by anti-HCV prevalence. We examined the relationship of cumulative number of dif-
ferent types of potential exposures found to be associated with anti-HCV prevalence by univar-
iate analysis (including having a permanent tattoo, ever received a blood transfusion and
received a medical injection within the last 6 months) and testing positive for anti-HCV. We
used logistic regression to estimate the adjusted OR of anti-HCV positivity for number of risk
factors (1, 2–3) compared with no risk factors.
Results
There were a total of 5,548 individuals who agreed to participate in the study and completed
the questionnaire, however, 5 lacked HCV testing results and were excluded, resulting in 5,543
subjects for inclusion in the analyses. The median age of our sample was 35 years (interquartile
range 21, 50) while the largest age group was participants age 5–18 years (Table 1). Among the
participants, there were more women (53.8%) than men (46.2%), and 62.4% resided in rural
areas (Table 1). The majority of participants, 81.9%, lived in households with an income of less
than 20,000 Indian rupees (about 300 US dollars) which is below the national average of
27,857 Indian rupees.[23] and 12.5% attended graduate school (Table 1).
When we examined potential exposures for HCV infection, 34.8% of participants had
received one or more medical injections in the previous 6 months in the weighted analysis.
When asked who administered their last medical injection, 20.4% identified a medical doctor
and 56.9% identified a registered nurse or registered medical practitioner (eg. medical care
provider not having the qualifications/training of a medical doctor). For those who had
received an injection in the last 6 months, 24% received it from a medical doctor, 71% from a
registered nurse or registered medical practitioner and 5% from other sources (eg. chemist or
pharmacist, unlicensed practitioner, or did not specify). Of the participants, 6.5% stated they
had received at least one blood transfusion. Additionally, 8.6% of patients had received a per-
manent tattoo, while few (0.1%) participants admitted to using injectable drugs.
Prevalence of hepatitis C virus infection in Punjab, India
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Table 1. Weighted and unweighted participant demographic characteristics and prevalence of potential exposures and risk factors associated with Hepatitis C
(HCV) infection, with percent testing positive for HCV antibodies (anti-HCV) and HCV-RNA cells.
Variables Unweighted
Population
Weighted
Population
% with positive anti-HCV (95% confidence
intervals)
% with HCV RNA (95% confidence
intervals)
Overall 5543 100% 3.6% (3.0%, 4.2%) 2.6% (2.0%, 3.1%)
Age Group (years)
5–18 1107 20.2% 0.7% (0.1%, 1.2%) 0.4% (0.0%, 0.8%)
19–29 1024 18.3% 1.7% (0.8%, 2.5%) 1.2% (0.5%, 1.9%)
30–39 998 18.0% 4.3% (2.9%, 5.7%) 3.1% (1.8%, 4.3%)
40–49 870 15.7% 6.2% (4.4%, 8.0%) 4.7% (3.1%, 6.2%)
50–59 721 13.0% 5.8% (3.9%, 7.7%) 4.5% (2.7%, 6.2%)
60 823 14.9% 4.3% (2.7%, 5.8%) 2.7% (1.4%, 3.9%)
Sex
Female 3005 53.8% 3.2% (2.5%, 3.9%) 2.3% (1.7%, 2.9%)
Male 2538 46.2% 4.0% (3.1%, 5.0%) 2.8% (2.1%, 3.6%)
Region
Urban 2083 37.6% 1.6% (1.1%, 2.2%) 1.0% (0.6%, 1.4%)
Rural 3460 62.4% 4.7% (3.8%, 5.7%) 3.5% (2.7%, 4.3%)
Household income (rupees)
<20,000 4546 81.9% 3.8% (3.1%, 4.5%) 2.7% (2.1%, 3.3%)
20,000 997 18.1% 2.5% (1.2%, 3.7%) 1.9% (0.8%, 2.9%)
Education
Never/Primary School 2114 37.7% 4.7% (3.6%, 5.8%) 3.8% (2.8%, 4.8%)
Middle/Secondary School 2735 49.8% 3.4% (2.6%, 4.1%) 2.1% (1.5%, 2.7%)
Graduate/Above 694 12.5% 1.1% (0.3%, 1.8%) 0.6% (0.1%, 1.2%)
No. injections in last 6
months
0 3639 65.2% 3.1% (2.4%, 3.8%) 2.2% (1.7%, 2.8%)
1–3 1155 21.1% 3.8% (2.6%, 5.0%) 2.5% (1.6%, 3.4%)
4–8 461 8.3% 4.7% (2.5%, 6.9%) 3.7% (1.6%, 5.7%)
>8 288 5.4% 7.0% (3.5%, 10.4%) 5.0% (2.1%, 7.9%)
Last injection given by
Medical Doctor 1149 20.4% 2.1% (1.2%, 2.9%) 1.3% (0.6%, 2.0%)
Registered Nurse/Medical
Practitioner
3090 56.9% 4.4% (3.6%, 5.2%) 3.3% (2.5%, 4.0%)
Other/Unknown 1304 22.7% 2.9% (2.9%, 4.0%) 1.9% (1.0%, 2.9%)
Number of times blood
donated
0 4808 86.5% 3.6% (2.9%, 4.2%) 2.5% (1.9%, 3.0%)
1–3 528 9.8% 3.3% (1.5%, 5.1%) 3.2% (1.4%, 5.0%)
4–6 115 2.1% 4.6% (0.5%, 8.6%) 3.6% (0.0%, 7.3%)
7 92 1.7% 5.3% (0.2%, 10.3%) 2.4% (0.0%, 5.8%)
Number of transfusions
received
0 5175 93.6% 3.4% (2.8%, 4.0%) 2.4% (1.9%, 2.9%)
1–3 353 6.3% 5.9% (3.2%, 8.6%) 4.6% (2.2% (6.9%)
>3 15 0.2% 25.8% (0.0%, 53.7%) 25.8% (0.0%, 53.7%)
Received a permanent tattoo
Yes 479 8.6% 5.2% (2.8%, 4.1%) 3.7% (1.9%, 5.4%)
No 5064 91.4% 3.4% (3.1%, 7.3%) 2.5% (1.9%, 3.0%)
Use of Injectable Drugs
(Continued)
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Overall, of the 5,543 persons tested for hepatitis C, 3.6% (95% CI: 3.0%, 4.2%) tested posi-
tive for anti-HCV (ever infected), and 2.6% (95% CI: 2.0%, 3.1%) tested positive for HCV
RNA, indicative of current infection. Among the 138 that tested positive for RNA, 130 were
successfully tested for genotype, the majority were classified as genotype 3 (61.2%), followed
by genotype 1 (27.5%) and genotype 4 (11.3%). No participants in our study were found to
have genotype 2. The proportions of RNA positive patients with each genotype differed by
province (p = 0.038).
Anti-HCV prevalence was higher among rural residents (4.7% [3.8%, 5.7%]) than urban
residents (1.6% [1.1%, 2.2%]) (Table 1). The proportion of persons testing positive for HCV
differed by district, ranging from 1.1% in Gurdaspur to 9.0% in Moga (Fig 1); however, this
study was designed to estimate prevalence for Punjab as a whole, not to estimate district level
prevalence.
When we examined anti-HCV prevalence by age, we found prevalence increased with age
up to 40–49 years where it peaked and then decreased with increasing age (Table 1). Overall,
prevalence among men and women was similar, (Table 1), and when stratified by age, there
were some small differences in seroprevalence by age groups among men and women (Fig 2).
Anti-HCV prevalence also decreased with increasing educational attainment, and was lower
among persons with higher income (Table 1).
When we examined the prevalence of anti-HCV antibody positivity by potential exposures
and risk factors, we found that rates were higher as the number of injections received increased
(see Fig 3), were highest for those whose last injection was administered by a nurse, registered
medical practitioner, or other non–medical doctor, increased with the number of transfusions
received, and also were higher among persons who had received a tattoo (Table 1). There were
no HCV infections among persons who had a history of receiving dialysis (Table 1); however,
the number persons associated with some of the exposures and risk factors, including dialysis
(n = 26) and injection drug use (n = 5), was small. When we examined anti-HCV prevalence
by the number of unique potential exposures, compared to persons without these potential
exposures, the HCV prevalence increased as the cumulative number of unique exposures
increased (Fig 4); the same analysis revealed that overall 43.7% of participants had one or more
type of potential exposure.
When we examined demographic and potential exposures and risk factors in a multivari-
able model, calculating adjusted odds ratios, we found similar findings to our bivariate analy-
sis: that testing positive for anti-HCV was associated with increasing age to age 40–49 years
with the odds decreasing slightly for older age groups, being male, rural residence, lower edu-
cational attainment, and receipt of blood transfusions (Table 2). Results were similar when the
analysis was restricted to adults (Table 3), and when the analysis was restricted to the two high-
est prevalence age groups– 40–49 and 50–59 years (Table 4). When we stratified the analysis
by urban and rural residence, all of the associations, except educational attainment, persisted
Table 1. (Continued)
Variables Unweighted
Population
Weighted
Population
% with positive anti-HCV (95% confidence
intervals)
% with HCV RNA (95% confidence
intervals)
Yes 5 0.1% 25.1% (0.0%, 66.8%) 25.1% (0.0%, 66.8%)
No 5538 99.9% 3.6% (2.9%, 4.2%) 2.5% (2.0%, 3.1%)
Any dialysis
Yes 26 0.4% 0.0% (0.0%, 0.0%) NA
No 5517 99.5% 3.6% (3.0%, 4.2%) 2.6% (2.0%, 3.1%)
https://doi.org/10.1371/journal.pone.0200461.t001
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among rural residents, while among urban residents, only age remained a significant predic-
tor. We did not find a difference in the likelihood of having HCV infection among those who
received a blood transfusion before 2002 and those who received one during or after 2002.
Fig 1. The percentage of participants sampled in each district that had Hepatitis C virus antibodies.
https://doi.org/10.1371/journal.pone.0200461.g001
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Discussion
This study, the first assessing the prevalence and risk factors for HCV infection in Punjab,
India, found an overall weighted prevalence of anti-HCV of 3.6% and HCV RNA of 2.6%. We
found that males, persons aged 40–59, and persons living in rural areas had the greatest odds
of being infected with HCV. Additionally, HCV infection was more common among those
who lacked education, received a blood transfusion, and had their last injection given by a
nurse or other medical practitioner as compared to a medical doctor. Through multivariable
analysis, we found no increased likelihood of being anti-HCV positive with increases in the
reported number of participants’ medical injections.
The association of HCV with age and rural residence has been observed in previous studies
from Punjab.[24] Also consistent with our analysis, studies from other countries have identi-
fied a particular age or birth cohort with a high prevalence of HCV compared to others.[25,
26] This cohort effect is demonstrated by persons born between 1945 and 1965, so called
“Baby Boomers” in the United States.[27, 28] In the United States, the higher HCV prevalence
among Baby Boomers has been attributed largely to injection drug use during their youth, the
lack of an HCV screening test for blood and blood products prior to 1990, and to the effect of
the HIV epidemic, recognized during the 1980s.[27, 28] In our study, noting the increasing
prevalence with age, it would be tempting to consider that transmission risk has decreased
over time and younger people are at lower risk, however, the youngest age groups studied,
Fig 2. Prevalence of Hepatitis C antibodies (95% confidence interval) by age category and sex.
https://doi.org/10.1371/journal.pone.0200461.g002
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5–18 and 19–29 year olds, had HCV seropositive rates of over 1% and 2% respectively, suggest-
ing that transmission risk persists in Punjab. In fact, a rise in prevalence of injection drug use
in Punjab has been described among teens and the youth population[29] and may present an
emerging risk for HCV infection in similarly aged populations in the years to come. Very few
admitted to injection drug use in our survey, which may reflect social desirability bias on the
part of participants.
Residence in a rural versus urban area was determined to be an effect modifier in our analy-
sis. Individuals in rural areas of Punjab had 2.5 times the odds of being anti-HCV positive as
those in urban settings after adjusting for covariates, a result comparable to other studies in
North India[30]. Upon stratification, we found that sex, age and blood transfusions were asso-
ciated with HCV among participants in rural areas, whereas in urban areas the only significant
association was with age. Poverty was not associated with infection. There is a paucity of
trained healthcare professionals in rural areas of Punjab, so healthcare in those regions is often
delivered by unqualified practitioners who may adopt unsafe injection practices,[31] possibly
contributing to the elevated prevalence of HCV among rural residents in Punjab in our study.
The finding that blood transfusions were a risk factor for HCV highlights the need for
improved blood safety practices in Punjab. Mandatory testing for HCV was implemented in
blood banks in India in 2002.[32] However, participants in our study who received their first
transfusion in 2002 or later were no less likely to be anti-HCV positive than those who received
transfusions before mandatory testing began. Despite the existence of statewide blood safety
guidelines, an association between receipt of a blood transfusion and having HCV infection
Fig 3. Prevalence of Hepatitis C antibodies by number of medical injections received in the last 6 months.
https://doi.org/10.1371/journal.pone.0200461.g003
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persisted in our study, regardless of when the blood transfusions were received, and may sug-
gest a persistent mode of HCV transmission in Punjab. These findings underscore the need for
greater enforcement and monitoring of blood banks to ensure proper testing procedures are
followed to prevent transmission in these settings.
Previous studies have also found inadequate infection control practices among healthcare
workers in India,[33, 34] however, the number of medical injections was not associated with
HCV after adjusting for covariates in our study. It is important to note that in a cross-sectional
study, to identify associations with medical practices is challenging. However, we found an
increased likelihood of being anti-HCV positive among those who received their last injection
from someone other than a medical doctor, a finding which was not specific to rural areas. A
2002 study in Punjab found that a considerable percentage of physicians with knowledge of
parenteral HCV transmission risk nevertheless reused needles and syringes with their patients.
[35] Furthermore, throughout India and in Punjab, treatment with injectable medicine is per-
ceived to be the treatment that ensures rapid therapeutic relief.[36] This belief has been incul-
cated over many years by physicians themselves, and there are financial incentives to deliver
treatment through a “procedure”, such as an injection.[36] Although increased availability of
disposable syringes helps temper these risks, healthcare workers throughout Punjab could ben-
efit from further training on safe injection practices to prevent the spread of HCV and other
diseases.
The prevalence of chronic HCV infection found in our study was slightly less than was
determined by a 2012 study in the region,[19] but in a population of roughly 28 million, still
translates to nearly three quarters of a million people chronically infected in the state of Punjab
alone. Future screening efforts need to address this burden of disease to identify infected indi-
viduals and link them to care and treatment. The results of this study can be used to target
screening and linkage to care efforts in the state, to ensure the highest yield of HCV infected
Fig 4. Prevalence of Hepatitis C antibodies by unique potential exposures (whether or not they had a permanent
tattoo, whether they had ever received a blood transfusion and whether in the last 6 months they had received a
medical injection).
https://doi.org/10.1371/journal.pone.0200461.g004
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Table 2. Weighted unadjusted and mutually adjusted odds ratios (OR) for having Hepatitis C antibodies (anti-HCV), by participant characteristics and risk factors,
overall and stratified by urban/rural status.
Total Odds Ratio (95%
Confidence Interval)
Urban Odds Ratio (95%
Confidence Interval)
Rural Odds Ratio (95%
Confidence Interval)
Variables Anti-HCV %
(95% CI)
Unadjusted
OR
Adjusted
OR
Anti-HCV %
(95% CI)
Unadjusted
OR
Adjusted
OR
Anti-HCV %
(95% CI)
Unadjusted
OR
Adjusted
OR
Total 3.6% (3.0%,
4.2%)
1.6% (1.1%,
2.2%)
4.7% (3.8%,
5.7%)
Age (years) NA
5–18 0.7% (0.1%,
1.2%)
0.39 (0.15,
1.01)
0.30 (0.12,
0.80)
0.5% (0.0%,
1.2%)
0.53 (0.10,
2.92)
0.47 (0.08,
2.64)
0.7% (0.0%,
1.5%)
0.34 (0.11,
1.08)
0.27 (0.09,
0.86)
19–29 1.7% (0.8%,
2.5%)
1 1 1.0% (0.0%,
1.9%)
1 1 2.1% (0.9%,
3.3%)
1 1
30–39 4.3% (2.9%,
5.7%)
2.64 (1.43,
4.89)
2.40 (1.30,
4.46)
1.0% (0.0%,
2.0%)
1.02 (0.25,
4.12)
1.00 (0.25,
3.98)
6.4% (4.2%,
8.6%)
3.17 (1.58,
6.37)
2.87 (1.44,
5.72)
40–49 6.2% (4.4%,
8.0%)
3.91 (2.20,
6.96)
3.41 (1.90,
6.11)
4.1% (2.0%,
6.2%)
4.36 (1.41,
13.5)
4.22 (1.39,
12.8)
7.5% (4.9%,
10.1%)
3.78 (1.94,
7.40)
3.21 (1.65,
6.25)
50–59 5.8% (3.9%,
7.7%)
3.66 (2.12,
6.31)
3.01 (1.73,
5.23)
2.4% (0.8%,
4.1%)
2.55 (0.83,
7.89)
2.67 (0.85,
8.36)
8.2% (5.2%,
11.3%)
4.18 (2.23,
7.82)
3.12 (1.68,
5.79)
60 4.3% (2.7%,
5.8%)
2.65 (1.43,
4.90)
1.82 (0.98,
3.38)
1.2% (0.0%,
2.5%)
1.20 (0.27,
5.44)
1.11 (0.22,
5.51)
5.8% (3.6%,
8.0%)
2.86 (1.43,
5.70)
1.96 (0.99,
3.86)
Rural (vs urban) 3.01 (2.00,
4.55)
2.53 (1.62,
3.95)
NA NA NA NA
Sex
Female 3.2% (2.5%,
3.9%)
1 1 1.7% (0.9%,
2.5%)
1 1 4.1% (3.1%,
5.0%)
1 1
Male 4.0% (3.1%,
5.0%)
1.28 (0.95,
1.72)
1.52 (1.08,
2.14)
1.6% (0.8%,
2.3%)
0.94 (0.49,
1.77)
1.08 (0.56,
2.06)
5.5% (4.1%,
7.0%)
1.38 (0.98,
1.93)
1.67 (1.13,
2.48)
Household income
0–20,000 Rupees 3.8% (3.1%,
4.5%)
1 1 1.8% (1.1%,
2.6%)
1 1 4.8% (3.8%,
5.7%)
1 1
>20,000 Rupees 2.5% (1.2%,
3.7%)
0.64 (0.38,
1.09)
0.95 (0.54,
1.66)
1.2% (0.4%,
2.0%)
0.65 (0.29,
1.44)
0.74 (0.32,
1.73)
4.7% (1.7%,
7.7%)
0.99 (0.50,
1.96)
1.06 (0.54,
2.10)
Education
None/Primary 4.7% (3.6%,
5.8%)
1 1 1.7% (0.6%,
2.8%)
1 1 5.9% (4.4%,
7.3%)
1 1
Middle/Secondary 3.3% (2.6%,
4.1%)
0.70 (0.52,
0.95)
0.81 (0.58,
1.13)
2.0% (1.1%,
2.8%)
1.16 (0.53,
2.56)
1.19 (0.49,
2.85)
4.2% (3.1%,
5.3%)
0.74 (0.55,
0.99)
0.74 (0.51,
1.07)
Graduate 1.1% (0.3%,
1.8%)
0.21 (0.10,
0.46)
0.37 (0.16,
0.82)
0.8% (0.0%,
1.5%)
0.45 (0.13,
1.50)
0.54 (0.13,
2.19)
1.6% (0.0%,
3.3%)
0.31 (0.09,
1.04)
0.37 (0.13,
1.09)
Last injection given by
Medical Doctor 2.1% (1.2%,
2.9%)
1 1 1.1% (0.3%,
2.0%)
1 1 3.1% (1.6%,
4.6%)
1 1
Registered Nurse/
Medical Practitioner
4.4% (3.6%,
5.2%)
2.16 (1.37,
3.42)
1.56 (0.97,
2.53)
2.3% (1.3%,
3.4%)
2.08 (0.87,
4.99)
1.71 (0.71,
4.12)
5.3% (4.2%,
6.4%)
2.16 (1.28,
3.66)
1.56 (0.88,
2.75)
Other/Unknown 2.9% (1.7%,
4.0%)
1.38 (0.78,
2.45)
1.25 (0.70,
2.23)
0.9% (0.1%,
1.7%)
0.80 (0.25,
2.52)
0.71 (0.23,
2.21)
4.3% (2.5%,
6.2%)
1.60 (0.71,
3.58)
1.44 (0.73,
2.84)
Number injections
received last 6 months
NA 1.02 (1.01,
1.03)
1.01 (0.99,
1.03)
NA 1.03 (0.99,
1.07)
1.02 (0.96,
1.08)
NA 1.01 (1.00,
1.03)
1.01 (0.98,
1.03)
Number of times
donating blood
NA 0.99 (0.93,
1.05)
0.96 (0.87,
1.05)
NA 0.99 (0.91,
1.08)
0.97 (0.88,
1.07)
NA 1.01 (0.94,
1.08)
0.96 (0.85,
1.08)
Number of blood
transfusions received
NA 1.36 (1.10,
1.69)
1.36 (1.10,
1.68)
NA 1.05 (0.69,
1.60)
0.99 (0.60,
1.64)
NA 1.56 (1.15,
2.10)
1.47 (1.10,
1.96)
Received a permanent
tattoo
(Continued)
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individuals. Screening efforts in Punjab should target rural districts and persons age 30 and
older. India’s expenditure on health care as a percentage of its gross domestic product (1.3% in
2015–2016) is among the lowest in the world, and the country has no system to monitor
patients.[37] Nationwide surveillance of hepatitis is also lacking in the country and focuses pri-
marily on hepatitis A and E.[38] Testing for incident HCV and HBV cases is only supported
by the country’s national Integrated Disease Surveillance Programme (IDSP) in outbreak situ-
ations.[38] Fortunately, treatment costs for HCV infection in India have decreased signifi-
cantly with the introduction of direct acting antiviral drugs in 2015, which have proven to be
highly effective.[39] In 2016 Punjab became the first state in India to make the commitment to
treat HCV patients free of charge.[40, 41] Through July 2017, over 32,000 patients have been
treated through the program,[40] representing an important step in control of the disease.
However, access to treatment alone cannot end the epidemic of HCV globally or in Punjab.
More initiative is needed with respect to disease awareness, diagnosis, and prevention. Never-
theless, with treatment options becoming more effective, affordable, and available to patients,
there is hope that Punjab could be reaching a turning point to mitigate the burden of HCV.
Our study is subject to several limitations. First, we were not able to independently verify
any of the responses on the questionnaire. Also, we could not determine the number of non-
responders, though it was reported from the field that interest was very high and 98% of house-
holds participated. As with any cross-sectional study that examines a chronic condition, it is
challenging to attribute risk due to lack of temporality, as the HCV infection could have
occurred at any time during the lifetime of the study subjects. The sampling method of this
study, which included multiple participants from a single household, could lead to potential
selection bias. Persons living together are more likely to exhibit similar behaviors and could
lead to disproportionate risks in the sample that may not be representative of the greater popu-
lation. Additionally, the sampling method of our study was not designed to produce precise
per-region prevalence estimates; there was a preponderance of people surveyed from rural
areas in districts that were found to have a high prevalence of HCV. These results should be
interpreted with caution, as this could lead to overestimation of the prevalence in these areas.
The face-to-face nature of the questionnaire creates the potential for social desirability bias.
Injection drug use is a significant risk factor for HCV, but self-report of this behavior was
extremely low (0.09%) among participants in our study despite reports of worrisome trends of
increased injection drug use in the state.[22] The number of persons associated with some of
the exposures and risk factors, notably dialysis (n = 26) and injection drugs (n = 5), was small,
making associations of these risk factors with HCV seropositivity difficult to determine. Thus
an important risk behavior may be substantially underrepresented in this analysis. Finally, we
cannot rule out false positive anti-HCV among those that tested negative for RNA.
Population studies provide critical data for planning control efforts of HCV. The effective-
ness and decreasing costs of DAAs are bringing control efforts within reach in many coun-
tries.[9] Programs that target screening and linkage to care for the highest risk populations in
Table 2. (Continued)
Total Odds Ratio (95%
Confidence Interval)
Urban Odds Ratio (95%
Confidence Interval)
Rural Odds Ratio (95%
Confidence Interval)
Variables Anti-HCV %
(95% CI)
Unadjusted
OR
Adjusted
OR
Anti-HCV %
(95% CI)
Unadjusted
OR
Adjusted
OR
Anti-HCV %
(95% CI)
Unadjusted
OR
Adjusted
OR
No 3.4% (2.8%,
4.1%)
1 1 1.6% (1.0%,
2.2%)
1 1 4.5% (3.6%,
5.5%)
1 1
Yes 5.2% (3.1%,
7.3%)
1.54 (0.97,
2.45)
1.21 (0.74,
1.98)
2.2% (0.1%,
4.3%)
1.42 (0.49,
4.09)
1.36 (0.49,
3.82)
6.9% (3.9%,
10.0%)
1.57 (0.94,
2.63)
1.17 (0.67,
2.05)
https://doi.org/10.1371/journal.pone.0200461.t002
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Table 3. Weighted unadjusted and mutually adjusted odds ratios (OR) for having Hepatitis C antibodies (anti-HCV), by participant characteristics and risk factors
overall and stratified by urban/rural status for adults age 18 or over.
Total Odds Ratio (95%
Confidence Interval)
Urban Odds Ratio (95%
Confidence Interval)
Rural Odds Ratio (95%
Confidence Interval)
Variables Anti-HCV %
(95% CI)
Unadjusted
OR
Adjusted
OR
Anti-HCV %
(95% CI)
Unadjusted
OR
Adjusted
OR
Anti-HCV %
(95% CI)
Unadjusted
OR
Adjusted
OR
Total 4.3% (3.6%,
5.1%)
1.9% (1.2%,
2.6%)
5.8% (4.7%,
6.9%)
Age
20–29 1.7% (0.8%,
2.5%)
1 1 1.0% (0.0%,
1.9%)
1 1 2.1% (0.9%,
3.3%)
1 1
30–39 4.3% (2.9%,
5.7%)
2.64 (1.43,
4.89)
2.43 (1.31,
4.51)
1.0% (0.0%,
2.0%)
1.02 (0.25,
4.12)
1.02 (0.26,
4.08)
6.4% (4.2%,
8.6%)
3.17 (1.58,
6.37)
2.89 (1.45,
5.77)
40–49 6.2% (4.4%,
8.0%)
3.91 (2.20,
6.96)
3.41 (1.90,
6.13)
4.1% (2.0%,
6.2%)
4.36 (1.41,
13.5)
4.36 (1.44,
13.2)
7.5% (4.9%,
10.1%)
3.78 (1.94,
7.40)
3.19 (1.64,
6.22)
50–59 5.8% (3.9%,
7.7%)
3.66 (2.12,
6.31)
2.96 (1.70,
5.16)
2.4% (0.8%,
4.1%)
2.55 (0.83,
7.89)
2.85 (0.92,
8.81)
8.2% (5.2%,
11.3%)
4.18 (2.23,
7.82)
3.03 (1.64,
5.63)
60 4.3% (2.7%,
5.8%)
2.65 (1.43,
4.90)
1.77 (0.95,
3.28)
1.2% (0.0%,
2.5%)
1.20 (0.27,
5.44)
1.13 (0.23,
5.68)
5.8% (3.6%,
8.0%)
2.86 (1.43,
5.70)
1.88 (0.95,
3.70)
Rural (vs urban) NA 3.20 (2.09,
4.89)
2.59 (1.63,
4.11)
NA NA
Sex
Female 3.6% (2.8%,
4.3%)
1 1 1.8% (0.9%,
2.7%)
1 1 4.6% (3.5%,
5.8%)
1 1
Male 5.2% (4.0%,
6.5%)
1.50 (1.10,
2.04)
1.73 (1.22,
2.44)
2.0% (1.0%,
3.0%)
1.12 (0.58,
2.15)
1.26 (0.66,
2.41)
7.3% (5.4%,
9.2%)
1.62 (1.15,
2.30)
1.89 (1.27,
2.81)
Household income
0–20,000 Rupees 4.7% (3.8%,
5.5%)
1 1 2.2% (1.3%,
3.2%)
1 1 5.8% (4.7%,
7.0%)
1 1
>20,000 Rupees 2.8% (1.3%,
4.2%)
0.58 (0.34,
1.00)
0.96 (0.54,
1.70)
1.2% (0.3%,
2.0%)
0.52 (0.22,
1.21)
0.66 (0.27,
1.60)
5.7% (2.1%,
9.3%)
0.97 (0.49,
1.92)
1.11 (0.57,
2.21)
Education
None/Primary 6.1% (4.6%,
7.5%)
1 1 2.2% (0.7%,
3.8%)
1 1 7.3% (5.5%,
9.1%)
1 1
Middle/Secondary 4.1% (3.1%,
5.0%)
0.66 (0.48,
0.90)
0.76 (0.54,
1.08)
2.3% (1.3%,
3.3%)
1.05 (0.45,
2.42)
1.21 (0.48,
3.06)
5.1% (3.8%,
6.5%)
0.69 (0.49,
0.97)
0.69 (0.47,
1.00)
Graduate 1.1% (0.3%,
1.8%)
0.17 (0.08,
0.36)
0.36 (0.16,
0.81)
0.8% (0.0%,
1.5%)
0.34 (0.10,
1.19)
0.59 (0.14,
2.48)
1.6% (0.0%,
3.4%)
0.21 (0.07,
0.63)
0.36 (0.12,
1.05)
Last injection given by
Medical Doctor 2.3% (1.2%,
3.3%)
1 1 1.0% (0.1%,
1.9%)
1 1 3.6% (1.7%,
5.5%)
1 1
Registered Nurse/
Medical Practitioner
5.3% (4.3%,
6.3%)
2.43 (1.48,
3.97)
1.75 (1.04,
2.92)
3.0% (1.6%,
4.1%)
2.95 (1.09,
7.98)
2.44 (0.89,
6.67)
6.4% (5.0%,
7.7%)
1.82 (1.02,
3.23)
1.61 (0.89,
2.90)
Other/ Unknown 3.6% (2.2%,
5.1%)
1.64 (0.90,
2.99)
1.45 (0.79,
2.66)
1.1% (0.1%,
2.1%)
1.13 (0.33,
3.95)
0.99 (0.28,
3.47)
5.7% (3.3%,
8.1%)
1.61 (0.81,
3.21)
1.56 (0.78,
3.14)
Number injections
received last 6 months
NA 1.02 (1.00,
1.03)
1.01 (0.99,
1.03)
NA 1.02 (0.98,
1.07)
1.02 (0.97,
1.07)
NA 1.01 (0.99,
1.03)
1.01 (0.99,
1.03)
Number of times
donating blood
NA 0.97 (0.89,
1.04)
0.95 (0.86,
1.04)
NA 0.98 (0.88,
1.08)
0.96 (0.87,
1.07)
NA 0.98 (0.90,
1.08)
0.95 (0.84,
1.07)
Number of blood
transfusions
NA 1.32 (1.07,
1.63)
1.37 (1.11,
1.70)
NA 1.03 (0.67,
1.59)
1.01 (0.61,
1.65)
NA 1.48 (1.11,
1.97)
1.49 (1.10,
2.00)
Received a permanent
tattoo
No 4.2% (3.4%,
5.0%)
1 1 1.8% (1.1%,
2.6%)
1 1 5.6% (4.4%,
6.8%)
1 1
Yes 5.5% (3.3%,
7.7%)
1.35 (0.85,
2.14)
1.17 (0.71,
1.92)
2.4% (0.1%,
4.6%)
1.28 (0.44,
3.72)
1.32 (0.47,
3.71)
7.4% (4.2%,
10.7%)
1.35 (0.81,
2.27)
1.13 (0.65,
1.99)
https://doi.org/10.1371/journal.pone.0200461.t003
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addition to addressing ongoing transmission risk, are likely to be the most successful and cost
effective. Population serosurveys, such as the study in Punjab presented here, can address key
information gaps and inform policy makers in efforts to alleviate the public health burden of
HCV infection across afflicted regions worldwide.[42]
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